#Germany #Fresenius Medical Care #Bad Homburg #Shervin Korangy #Helen Giza

Fresenius Medical Care Welcomes New Leadership

Fresenius Medical Care (FMC), recognized globally as a leader in renal healthcare, has announced the appointment of Shervin J. Korangy as the new Chief Executive Officer (CEO) and Chair of the Management Board, effective from October 12, 2026. This significant leadership change comes as the company prepares to embark on the next phase of strategic growth and innovation, building upon the groundwork laid by his predecessor, Helen Giza.

Transitioning Leadership

Helen Giza has served as CEO for four years, leading the organization through transformative changes, including the implementation of the FME25+ program, which has proven to be key in optimizing the company’s portfolio. Under her stewardship, FMC managed to streamline processes, improve operational efficiency, and reduce costs by approximately €1.2 billion, cementing a robust foundation for future endeavors. Her leadership has enabled the company to become more resilient, effective, and profitable.

As Shervin Korangy steps into this pivotal role, he brings with him extensive leadership experience and a wealth of knowledge gained from working across the healthcare and life sciences sectors. Before joining FMC, he successfully led BVI Medical, transforming the company into a globally recognized name in surgical eye care.

Shervin Korangy’s Vision for FMC

Shervin Korangy’s appointment is pivotal at a crucial juncture for Fresenius Medical Care. With a vision centered on sustainable growth, he is set to lead the organization towards further innovation and market leadership. Korangy aims to enhance the value provided to patients, customers, and shareholders by fostering an environment that encourages creativity and responsiveness to evolving healthcare demands.

In his statement regarding his new role, Korangy expressed his gratitude for the opportunity and underscored the responsibility he feels towards the organization’s employees and the patients it serves. “Healthcare is evolving rapidly, and FMC possesses a unique global platform to address patient needs effectively,” he noted. His strategic focus will prioritize expanding access to care and improving medical outcomes while pursuing long-term profitable growth.

A Legacy of Efficient Leadership

During her tenure, Giza effectively tackled key operational and financial challenges, making the organization more resilient and improving overall profitability. As she makes way for Korangy, she reflects on her time at the helm with pride, noting the strong foundation established for the company's future success. Giza is confident that Korangy, with the support of FMC's strong management team, is well-positioned to steer the company towards achieving its ambitious goals.

A Look at the Future

Fresenius Medical Care operates a vast network of 3,513 dialysis clinics worldwide, providing treatment for approximately 290,000 patients. As the demand for renal care continues to grow, FMC is intent on leveraging its expertise to introduce innovative treatment options and enhance the overall quality of service for its patients. Korangy is expected to play a significant role in this ongoing effort for improvement and excellence.

In conjunction with Korangy's promotion, the Supervisory Board has appointed Ann Custin as his successor on the Board, ensuring that the leadership team remains strong and capable as the company transitions into this new chapter.

FMC remains committed to its mission of providing high-quality healthcare solutions to individuals with renal diseases. Under Shervin Korangy’s leadership, the organization is poised to advance its strategic agenda, creating sustainable value and setting new benchmarks in healthcare excellence.

As the healthcare landscape continues to evolve, with increasing patient needs and new care models, the leadership at Fresenius Medical Care stands ready to navigate these challenges, focused on delivering optimal care and fostering innovation.